Kineta, Inc. is developing an array of new drug candidates designed to restore the immune system to normal function. We are designing novel, next generation medicines to respond to the needs of millions of people facing disease around the world. Our products will also respond to the tremendous demand from the pharmaceutical industry for high quality drug candidates. We anticipate a robust market for our products and eventually, strong demand from patients and healthcare providers.

Kineta's drug development programs are concentrated in two critically important areas: treatments for autoimmune diseases and treatments for viral diseases. In both realms, Kineta's novel drug targets spring from global expertise in the field of human immunity. Kineta is advancing entirely new classes of drugs that tap into powerful, recently discovered cellular channels that control the body's defense mechanisms. Our scientists believe these future therapies will be more effective, more tolerable and have fewer side effects because they work in concert with the immune system.